• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

    11/18/24 8:00:00 AM ET
    $NXPL
    $OPK
    Telecommunications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXPL alert in real time by email

    OPKO Healthcare's Veterinary Care Products to be Introduced at Asia's Largest Health and Nutrition Tradeshow

    Company Invited to Present at Special Event Hosted by U.S. Consulate General During the Expo

    COCONUT GROVE, Fla., Nov. 18, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global e-commerce provider, today announced that it is participating in the 2024 China International Natural Health & Nutrition Expo (NHNE), Asia's largest exhibition focused on the sales and marketing of health, nutrition and dietary supplement products, as the Company continues to ramp-up sales and promotional activities in China.

    NextPlat Corp. logo (PRNewsfoto/NextPlat Corp.)

    Held at the Wuhan International Expo Center from November 20th to the 22nd, the China International Natural Health & Nutrition Expo is the premier exhibition focused on health, nutrition and dietary supplements. The bi-annual event is the largest of its kind in Asia with 1,200 suppliers from more than 30 countries and regions, attracting as many as 120,000 omnichannel buyers. At the event, an expanded array of products from OPKO Health Europe, a unit of OPKO Health, Inc. (NASDAQ:OPK) (OPKO), including an initial selection of veterinary and animal care products will be on display for attendees.

    Additionally, NextPlat has also been invited by the U.S. Consulate General in Wuhan to present OPKO products during the NHNE expo to a specially selected group of Chinese buyers interested in U.S. healthcare products.

    "Over the past few weeks, with the support of our in-country marketing and sales partner, we have seen demand for our OPKO products significantly increase as we ramp-up online and offline promotional activity. Through participation in NHNE, we have access to thousands of potential new retail and distribution partners making it the ideal venue for us to introduce OPKO's animal health products," said David Phipps, President of NextPlat and CEO of Global Operations. "Based upon strong interest in our initial product offerings, through increased inventory, and the introduction of new products for health, wellness and pets, we are confident in the significant sales potential we see in China."

    As announced earlier this year, the Company has begun the sales of OPKO products in China and supported by a new in-country marketing partner, has recently engaged Chinese social media influencers and conducted experiential marketing programs. The Company is currently in the process of launching new online OPKO storefronts on leading digital sites in China including WeChat which has over 1.3 billion monthly users, and on JD.com, China's second largest e-commerce platform which attracts in excess of 560 million users annually. Additionally, the Company is seeking to secure physical distribution of OPKO products into major retail chains, pharmacies and grocery stores during 2025.

    OPKO is a global diversified diagnostic and pharmaceutical healthcare company with over 5,500 employees spanning nine countries. The distribution agreement with OPKO's European division represents the first relationship resulting from the Company's Florida E-commerce Development program which includes a merchant sourcing agreement with Alibaba's Tmall Global designed to provide American businesses with easy access to the Chinese consumer market.

    About NextPlat Corp

    NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the Company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care LLC.

    Forward-Looking Statements

    Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services, or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to launch new data-driven tools and services and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

    Media and Investor Contact for NextPlat Corp:

    Michael Glickman

    MWGCO, Inc.

    917-397-2272

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-to-showcase-opko-healthcare-products-at-the-2024-china-international-natural-health--nutrition-expo-302308105.html

    SOURCE NextPlat Corp.

    Get the next $NXPL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXPL
    $OPK

    CompanyDatePrice TargetRatingAnalyst
    OPKO Health Inc.
    $OPK
    11/20/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    10/31/2025$1.60Buy → Hold
    Jefferies
    OPKO Health Inc.
    $OPK
    4/25/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    OPKO Health Inc.
    $OPK
    12/15/2022$3.00Buy
    H.C. Wainwright
    OPKO Health Inc.
    $OPK
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $NXPL
    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NextPlat's PharmcoRx Deploys Artificial Intelligence-Powered Prescription Processing Technology Supporting Expanded Nationwide Fulfillment Efforts

    AI Technology to Automate Prescription In-Take, Improve Processing Accuracy and Reduce Costs as Fulfillment Volume GrowsHALLANDALE BEACH, Fla., April 16, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that its PharmcoRx subsidiary has deployed state-of-the-art artificial intelligence (AI)-powered prescription in-take and processing technology into its pharmacy management system. This AI technology will support PharmcoRx as it seeks to improve the efficiency of its medication fulfillment

    4/16/26 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    NextPlat's GTC Receives Satellite Enabled Internet of Things (IoT) Contracts Valued at $400,000 as its Government and Military Pipeline Surpasses $1.2 Million Through Q1 2026

    Early 2026 Contract Pipeline Continues to Expand as Government and Military Demand for Connectivity Solutions GrowHALLANDALE BEACH, Fla., April 14, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that its Global Telesat Communications Ltd (GTC) subsidiary continues to see strong demand for satellite-enabled Internet of Things (IoT) hardware from leading providers including Globalstar and Iridium, receiving new orders valued at approximately $400,000 in support of an existing military end-

    4/14/26 7:45:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    OPKO Health's ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19

    WESTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial evaluating MDX2301 for the prevention of COVID-19. MDX2301 is a tetravalent bispecific antibody that has the potential to neutralize all known variants of SARS-CoV-2. The study is evaluating the safety and tolerability of MDX2301 administered via different routes in healthy volunteers and in adults at high risk for severe COVID-19. By combining multiple antibody binding domains in a single molecule, MDX2301 is designed to provide high potency and greater breadth compared to conventional monocl

    4/8/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Chairman Frost Phillip Md Et Al bought $768,807 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/21/25 5:07:09 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $771,328 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/20/25 6:10:53 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $759,115 worth of shares (580,000 units at $1.31) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/19/25 5:02:21 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Paganelli John A

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:25:05 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Uppaluri Subbarao V

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:16:55 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Uppaluri Subbarao V

    3 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:10:17 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    11/20/25 8:08:07 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opko Health downgraded by Jefferies with a new price target

    Jefferies downgraded Opko Health from Buy to Hold and set a new price target of $1.60

    10/31/25 8:18:38 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    4/25/25 8:32:28 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    SEC Filings

    View All

    NextPlat Corp filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - NextPlat Corp (0001058307) (Filer)

    4/6/26 12:31:13 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    NextPlat Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NextPlat Corp (0001058307) (Filer)

    3/31/26 4:27:48 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    SEC Form 10-K filed by NextPlat Corp

    10-K - NextPlat Corp (0001058307) (Filer)

    3/31/26 4:24:55 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    $NXPL
    $OPK
    Leadership Updates

    Live Leadership Updates

    View All

    NextPlat Appoints Rodney Barreto as Chairman of the Board and David Phipps as Chief Executive Officer to Lead Ongoing Business Refocusing Efforts

    Company Executes on Initiatives Including New Business Development, Corporate Reinvestment and Implements Additional Cost-Cutting Initiatives HALLANDALE BEACH, Fla., Sept. 9, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide, today announced that as part of the Company's ongoing business refocusing plans, it has named Rodney Barreto as its permanent Chairman of the Board and David Phipps as its permanent Chief Executive Officer. Messrs. Barreto and Phipps were both serving in interim roles following the pas

    9/9/25 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    NextPlat Accelerates Healthcare Growth with New Leadership and Expanded Sales, Marketing, and Technology Investments

    Veteran Healthcare Leadership to Drive Business Process Improvement, Enhanced Customer Service and Support the Introduction of New Services for 340B and Long-term Care Providers COCONUT GROVE, Fla., Aug. 26, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today announced the strategic expansion of its healthcare operations. This expansion includes a series of developments highlighted by the appointment of new senior leadership and investment into its healthcare operations designed to support its growth in

    8/26/25 8:02:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

    WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

    9/23/24 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

    SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/15/24 4:39:33 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OPKO Health Inc.

    SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

    11/13/24 4:30:24 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

    SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/12/24 4:54:06 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Financials

    Live finance-specific insights

    View All

    NextPlat Reports $54 Million in Revenue for Full Year 2025 as Business Turnaround Initiatives Support Operational Profitability Goals in 2026

    Refocusing and Cost Cutting Efforts Now Delivering Operational Improvement Including Sequential Margin Expansion and Significant Cost ReductionsHALLANDALE BEACH, Fla., March 31, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced the financial results for the year ended December 31, 2025, reflecting the performance of its healthcare and e-commerce operations. "The closing of 2025 marks

    3/31/26 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    NextPlat to Release Full Year 2025 Results on Tuesday, March 31, 2026

    Investor Conference Call Scheduled for Tuesday, March 31, 2026 at 8:30 a.m. EasternHALLANDALE BEACH, Fla., March 25, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that it will release its financial results for the full year ended December 31, 2025 on March 31, 2026. NextPlat's CEO, President and CEO of Global Operations, David Phipps, its Chief Financial Officer, Amanda Ferrio and

    3/25/26 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

    MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regeneron's proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront

    2/26/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care